The company will strengthen its position in the ‘green solvent’ market by increasing its capacity by 20% to 120,000 MTPA from 100,000 MTPA before the end of current fiscal
The company has reported total income of Rs. 6276.54 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 129.96 crores during the period ended June 30, 2022.
He has over 25+ years of experience in the pharmaceutical Industry and has been working with the company for the past 6 years
The company has reported total income of Rs. 918.9 crores during the period ended June 30, 2022.
Profit after Tax stood at Rs. 105 crore as compared to Rs. 119 crore on account of higher treasury income in Q1 FY22, non-cash ESOP cost, depreciation on account of acquired brands and finance costs in Q1 FY23
Both the plants have a total Capex of Rs. 75 crore and expected production timeline is Q3 FY23
Sandu Kumarvin is an Ayurvedic digestive and immunity booster for children and also offers several other benefits.
The CSC shall hold Market Authorisation (MA) to sell SRL's BUSALFAN, API exclusively in China territory.
The total financial outlay of the scheme is Rs.500 crore for a period of five years from 2021-22 to 2025-26.
Subscribe To Our Newsletter & Stay Updated
